surgery of transposition, but the present approach of primary balloon atrial septostomy followed bv the Mustard operation will continue to be the mainstay of treatment for some time.
Politics and pharmaceuticals
The drug industry has always ranked high among the capitalist ogres that enrage socialist politicians, and last year yet again the Labour Party's annual conference called for its wholesale nationalisation. A more moderate line has appeared in a discussion document1 published last week by a Labour Party working group chaired by Dr David Owen. This argues the case for the National Enterprise Board taking over "at least one" British company with a substantial interest in pharmaceuticals, so giving the State a foothold in the industry. The State company could, it is said, make better use ofthe legal provisions which allow licences to be granted to companies to manufacture drugs covered by patents-or at least the possibility would be there to discourage companies from making very high profits on a particular drug. The State company could undertake long-term research in areas of social importance but little commercial attraction; and it could provide the Government with data on the true costs of production and research within the industry. Other recommendations include a revision of the voluntary pricing system to bring it within statutory price controls and the use of planning agreements to encourage companies to pursue research developments of practical importance to the NHS.
Predictably, the discussion document also attacks the cost and content of much current pharmaceutical advertising and the quality of information about drugs supplied to doctors. It calls for a substantial cut in sales promotion (the subject of current private discussions between the industry and Dr Owen in his Government capacity), the abolition of free gifts and samples, and tighter controls on the content of pharmaceutical advertising. Prescribers' Journal should be expanded; doctors should be made more aware of the relative costs of similar drugs; and it discusses the possibility of ranking drugs into those of first choice for specific indications and those which are second or third line choices.
The tone ofthe document is reasoned enough, and the case it argues plausible-given its No one disputes that there is some truth in the criticisms made of the current practices of the drug industry in Britain, though the picture painted by Dr Owen's group is naturally darker than most. But the changes, controls, and restrictions proposed in the document are based on beliefs and not on facts. What evidence is there that State-directed research is of greater benefit to the community than that directed by commercial concerns ? Already the universities and the research councils, with their enviable record of achievement and independence, are facing massive cuts in their budgets. Is there really any evidence that Government money would be better spent on acquiring a research-based drug firm? The same criticism may be made of the rest of the document. The ideas sound reasonable and are well intentioned; yet the NHS patient gets his drugs more cheaply than in almost any other technically advanced country this side of the iron curtain, and it makes little sense to upset an applecart that looks in betterthan-average shape. Certainly it is part of the socialist tradition to be active and reformist: but the Labour Party's preoccupation with the pharmaceutical industry, like its obsession with private beds, betrays its poor assessment of the real priorities for the nation's health. International studies of risk factors for coronary heart disease Mortality rates from coronary heart disease (CHD) vary enormously throughout the world; even among the developed countries the variation is remarkable. The highest rates in middle-aged men are found in Finland-for men aged 45-54 years the rate is over 400 per 100 000 per year-and in the United States the rates are nearly as high. Scotland is well known to have higher rates than England and Wales, though no clear explanation can be given for this, and the rates in Britain as a whole are substantially higher than in several other European countries, including Sweden and Italy. The lowest mortality in an industrialised country is found in Japan; for middle-aged men the rate is less than 10% of that in Finland.
Analysis of trends in death rates' and assessment of reporting methods2 suggest that the international differences are not due simply to variations in diagnostic habits.
Community studies have identified the major factors associated with an increased risk of clinical CHD, and comparisons of the results obtained in different countries have indicated that the levels of these "risk factors" tend to be higher where death rates for CHD are higher. Nevertheless, such are the errors that can be introduced if different methods are used, for example, for estimating serum cholesterol, for classifying electrocardiograms, or even for defining CHD, that comparisons of results from uncoordinated studies may be quite misleading. The use of reference laboratories and standardised classifica-tion systems3 have contributed much to improving the comparability of data from separate studies, but the most effective way of reducing methodological bias is by collaboration between workers using the same research protocol in different countries.
One of the earliest examples of a collaborative study, made shortly after the second world war, was a comparison of serum cholesterol levels in American and Italian men. 4 The finding that the levels were higher and that they continued to rise with age after 35 years in the more CHD-prone Americans helped to stimulate the subsequent world-wide epidemiological study of blood lipids. Collaborative necropsy studies5 have shown coronary atherosclerosis to be more common in countries with higher death rates from CHD and that the severity of atherosclerosis is associated with hypertension and diabetes mellitus. A study of American and British post office and telephone workers6 showed that evidence of cardiac ischaemia was more frequent in the Americans, in all smoking categories. Factors associated with the Americans' greater adiposity were thought likely to explain their adverse experience of cardiovascular disease. The Seven Country Study7 has indicated that blood pressure and serum cholesterol tend to have higher values in men living in countries where CHD is more common but that other factors related to the incidence of CHD vary from one country to another. Further analysis of these data8 has shown that the Americans have an unexplained excess incidence of clinical CHD over the Europeans which is not due to differences in age, systolic blood pressure, serum cholesterol, smoking habit, or body mass. Recently another comparative study has been reported by two groups investigating men aged 40 selected at random in Edinburgh and Stockholm. 9 Many risk factors were considered, but the greater number of cigarette smokers and higher levels of systolic blood pressure and fasting serum triglycerides in Edinburgh men were thought to be the most significant findings.
However, in these studies it has not been possible to separate the genetic from the potentially modifiable environmental determinants of risk. Studies in which the characteristics of migrants are compared with those remaining in the country of origin have the advantage that comparisons are between people of the same genetic stock. Blood pressure has been shown to be higher in those who have moved from rural or urban areas'011 (though there is some evidence that this might be explained by differences in weight'2); but migrants from countries with low rates of CHD who move to high risk countries retain lower blood pressure levels when compared with natives of their host country.'3 14 Other factors, including serum lipids, 1-hour blood sugar, and relative weight, have been shown to differ between men living in Japan and Japanese men in Hawaii and California. '5 16 Nevertheless, migrants may differ from the populations they leave, for reasons associated with their decision to leave.
Cassel'7 has commented that if migrant studies are to be of real value in disentangling the relative importance of physical and psychosocial factors then the usual cross-sectional study is inadequate. The ideal experiment is one in which migrants are identified before they migrate, are compared with nonmigrants ofthe same population so that selective factors may be identified, and are followed over time in their new environment. A natural experiment of this design has occurred in the planned migration of the Tokelau Islanders to New Zealand, and its evaluation should lead to a greater understanding ofthe effects of migration than has previously been possible. '8 The risk factors examined in international studies have tended to be those that have already been identified elsewhere. Because international studies pose problems of control, comparability, and cost that far exceed those of more limited ambition, their task should be to provide unique insights into the epidemiology of CHD which cannot be obtained from local or regional comparisons within a country. To this end, the World Health Organisation has been encouraging the use of a common basic protocol for the establishment of ischaemic heart disease registers,'9 20 so that the natural history and management of coronary heart attacks may be compared between countries. WHO is also sponsoring a collaborative trial of preventive measures in four European countries.2' A preventive trial requires such large numbers to detect statistically significant changes in incidence and mortality that it may be difficult for one country to bear the cost of carrying it out alone. By international co-operation the power of the study can be made sufficient, the consistency of the findings examined, and the effects ofmodifying the risk factors assessed. Benign proliferative lesions of the breast While clinical attention is rightly focused on carcinoma as the most important disease of the breast, benign mammary proliferations are, in fact, much more frequent than malignant ones. Indeed, the most common lesion of the breast is cystic hyperplasial-also called mammary dysplasia, a term to be preferred since cystic change is not invariable. This condition has its peak incidence in women between the ages of 30 and 50 and is believed to be the result of imbalance of ovarian hormones, probably oestrogen excess and progesterone deficiency. The breast is lumpy, and it may be tender especially during the premenstrual phase of the menstrual cycle. In more advanced cases there are discrete, tense, cystic masses which may fluctuate in size from time to time. The initial histological change is moderate overgrowth and dilatation of ducts, and this may be followed by sufficient epithelial overgrowth to occlude their lumina, a condition called epitheliosis. If 
